CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study

Description

Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.

Conditions

Cardiac Amyloidosis

Talk to us

Study Overview

On this page

Study Details

Study overview

Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.

Pilot Study Evaluating Supervised Cardiac Rehabilitation in Patients With Cardiac Amyloidosis

CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study

Condition
Cardiac Amyloidosis
Intervention / Treatment

-

Contacts and Locations

Charlotte

Sanger Heart and Vascular Institute, Charlotte, North Carolina, United States, 28204

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age \> 18
  • * New York Heart Association (NYHA) Class I-III Heart Failure
  • * Able to Exercise
  • * On stable treatment for their cardiac amyloidosis or under active surveillance
  • * Life expectancy of at least 6 months
  • * Ability to understand and the willingness to sign a written informed consent document in English, and the willingness/ability to comply with the protocol activities
  • * Participant must be able and willing to follow the cardiac rehabilitation activities
  • * Inability to provide informed consent
  • * Inability to commit to in-person supervised exercise sessions for three one-hour sessions a week for 12 weeks
  • * NYHA Class IV Heart Failure
  • * Pulmonary disease requiring home oxygen
  • * Gait instability or history of prior falls
  • * In the opinion of the Principal Investigator, have a clinically significant comorbid disease that is likely to affect the ability of the patient to complete the trial, interfere with their ability with measurement of self-reported outcomes.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Wake Forest University Health Sciences,

Jai Singh, MD, PRINCIPAL_INVESTIGATOR, Wake Forest University Health Sciences

Study Record Dates

2026-01